Grifols Terre Haute Indiana represents a major investment in local biotherapeutics manufacturing and regional employment. This facility advances plasma collection and fractionation capabilities while supporting Indiana's life sciences sector.
Below is a concise overview of operations, compliance, and logistics relevant to stakeholders and community partners.
| Facility | Capacity | Regulatory Oversight | Key Partners |
|---|---|---|---|
| Grifols Plasma Facility, Terre Haute | Plasma collection and fractionation | FDA, Indiana State Dept. of Health | Local healthcare networks, logistics providers |
| Operational footprint | Multiple collection centers | Quality compliance | Community donors |
Plasma Collection Standards In Terre Haute
Grifols operates under strict FDA and state guidelines to ensure donor safety and product integrity. Collection centers in Terre Haute follow validated procedures and site-specific controls.
Donor Screening Protocols
Each donor completes health questionnaires and mini-physicals. Criteria include travel history, medication use, and laboratory results to determine eligibility on the day of donation.
Processing and Traceability
Plasma is collected using automated apheresis under sterile conditions. Full traceability links each unit to donor identifiers, session timestamps, and batch test results.
Regulatory Compliance And Quality Assurance
Regulatory compliance is central to Grifols operations in Terre Haute. The facility aligns with current good manufacturing practices and undergoes regular inspections.
- Adherence to FDA 21 CFR Part 11 electronic records requirements
- Environmental monitoring programs for cleanroom areas
- Documented change control and deviation management
- Periodic validation of equipment and laboratory assays
Economic Impact On The Terre Haute Region
Grifols investment in Terre Haute supports skilled jobs, supplier relationships, and community initiatives. Local vendors and service providers participate in site infrastructure and maintenance.
Direct And Indirect Employment
The facility employs phlebotomists, lab technicians, engineers, and quality professionals. Additional roles emerge in logistics, administration, and facility services.
Supply Chain Integration
Regional partners contribute materials, transportation, and IT services. Collaborative planning supports reliable inventory and timely distribution of pharmaceutical-grade plasma proteins.
Community Engagement And Safety Initiatives
Community outreach explains donation processes, addresses concerns, and highlights public health benefits. Safety drills and continuous training reinforce emergency preparedness.
Public Health Benefits
Plasma-derived therapies treat immunodeficiencies, autoimmune conditions, and bleeding disorders. Reliable local supply chains improve patient access across Indiana.
Operational Excellence And Future Growth
Continuous improvement initiatives, automation, and expanded collection capacity position Grifols Terre Haute Indiana to meet growing demand for reliable plasma-derived medicines.
- Maintain rigorous donor screening and testing standards
- Invest in advanced apheresis and fractionation technologies
- Strengthen supplier partnerships and regional logistics
- Engage community stakeholders through transparent communication
FAQ
Reader questions
What diseases are treated with plasma from the Terre Haute facility?
Plasma collected at the Terre Haute site is used to manufacture therapies for primary immunodeficiency, hereditary angioedema, and certain bleeding disorders.
How does Grifols ensure donor privacy in Terre Haute?
Donor identifiers are encrypted, and health data are stored in secure systems compliant with HIPAA and FDA requirements, limiting access to authorized personnel only.
Are there travel requirements for donors visiting Terre Haute locations?
Donors must follow site-specific instructions regarding arrival time, documentation, and health screening; recent travel to certain regions may temporarily defer donation.
How are local suppliers selected for the Terre Haute facility?
Suppliers undergo quality audits, contract reviews, and performance monitoring to ensure consistent delivery of materials that meet Grifols specifications.